Aurinia Pharmaceuticals: Silencing Doubters, But Competition Looms (NASDAQ:AUPH)

Core Insights - Aurinia Pharmaceuticals Inc. (AUPH) has experienced significant developments recently, including continued growth in its drug Lupkynis, the approval of a competitor's drug for lupus nephritis, and a request for information from the FDA [1] Company Developments - The earnings update from Aurinia Pharmaceuticals indicates ongoing growth in the sales of Lupkynis, which is a positive sign for the company's financial health [1] - A competitor's drug has received approval for lupus nephritis, which may impact Aurinia's market position and competitive landscape [1] - The FDA has requested additional information, which could influence the regulatory pathway for Aurinia's products [1]